PHIL.MI Stock - Philogen S.p.A.
Unlock GoAI Insights for PHIL.MI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $74.00M | $23.13M | $23.71M | $2.50M | $4.78M |
| Gross Profit | $54.42M | $5.67M | $10.53M | $-8,136,000 | $-5,054,000 |
| Gross Margin | 73.5% | 24.5% | 44.4% | -326.0% | -105.8% |
| Operating Income | $37.73M | $-8,840,000 | $240,000 | $-16,775,000 | $-12,129,000 |
| Net Income | $45.29M | $-6,161,000 | $-5,376,000 | $-15,725,000 | $-13,285,000 |
| Net Margin | 61.2% | -26.6% | -22.7% | -630.0% | -278.0% |
| EPS | $1.12 | $-0.15 | $-0.13 | $-0.40 | $-0.45 |
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase I clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy.
Visit WebsiteEarnings History & Surprises
PHIL.MIEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q3 2025 | Sep 23, 2025 | $5.53 | $-0.37 | -106.7% | ✗ MISS |
Q2 2025 | Jun 28, 2025 | — | — | — | — |
Q2 2025 | May 23, 2025 | — | — | — | — |
Q1 2025 | Mar 27, 2025 | $6.15 | $0.76 | -87.7% | ✗ MISS |
Q4 2024 | Dec 6, 2024 | $-0.32 | $0.76 | +335.9% | ✓ BEAT |
Q3 2024 | Sep 25, 2024 | $-0.32 | $-0.19 | +39.8% | ✓ BEAT |
Q2 2024 | Jun 24, 2024 | — | $-0.19 | — | — |
Q1 2024 | Mar 27, 2024 | $-0.29 | $-0.17 | +40.5% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | — | $-0.17 | — | — |
Q3 2023 | Sep 28, 2023 | $-0.23 | $0.09 | +141.3% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | — | $0.09 | — | — |
Q1 2023 | Mar 29, 2023 | $-0.19 | $-0.09 | +52.3% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | — | $-0.09 | — | — |
Q3 2022 | Sep 29, 2022 | $0.07 | $0.05 | -30.1% | ✗ MISS |
Q2 2022 | May 29, 2022 | — | $0.02 | — | — |
Q1 2022 | Mar 30, 2022 | $-0.24 | $-0.09 | +62.8% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-0.17 | — | — |
Q3 2021 | Sep 28, 2021 | $-0.23 | $-0.21 | +7.4% | ✓ BEAT |
Q2 2021 | Apr 28, 2021 | — | $-0.11 | — | — |
Latest News
Frequently Asked Questions about PHIL.MI
What is PHIL.MI's current stock price?
What is the analyst price target for PHIL.MI?
What sector is Philogen S.p.A. in?
What is PHIL.MI's market cap?
Does PHIL.MI pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PHIL.MI for comparison